Company
Poolbeg Pharma PLC
LON:POLB
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.
125 stories · page 1 of 2
Archive
Small Cap Feast - Poolbeg Pharma, Power Metal Resources and more...
16 January 2023*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners:No joiners today.Leavers:No leavers today.What’s cooking in the IPO kitchen?**Celsius Resources intends to j
Poolbeg Pharma identifies possible new RSV treatments as infection rates soar
These candidates are well positioned to enter clinical trials quickly
Poolbeg Pharma targets first half of next year for first trial of oral diabetes/anti-obesity drug
The company will use a newly-licensed coating technology
Poolbeg Pharma says new flu jab completes first clinical trial
The challenge trial was designed to evaluate the effect of POLB 001 on inflammatory responses in 36 healthy volunteers
Poolbeg Pharma to hold capital markets day this month
Attendees, which will comprise of analysts, investors and media, will gain a greater understaind of Poolbeg’s model and development strategy, it said
Poolbeg Pharma: Market starting to recognise the impact of recent progress
The shares have rocketed 41% in the last five trading days
Poolbeg Pharma consortium wins grant to develop oral vaccines
The company said it is continuing to target further non-dilutive funding opportunities
Poolbeg Pharma and partner find first RSV drug targets using AI
It partnered with OneThree Biotech to carry out the research
Poolbeg Pharma CEO buys stock in the drug developer
Jeremy Skillington bought 718,733 shares at 4.78p each
Poolbeg Pharma enhances the patent protection around flu asset
The company expects to receive the formal US patent grant "in due course"
Poolbeg Pharma signs exclusive deal with University College Dublin for vaccine candidate
POLB 003 is a prospective treatment to prevent Melioidosis
Poolbeg Pharma has made significant progress, says upbeat City broker
The company's corporate broker finnCap pointed to a series of potential inflexion points for the drug developer
Poolbeg Pharma eyes busy second half as value inflexion point nears
POLB 001, a treatment for severe flu, is the company's most advanced asset
Archive
Small Cap Movers: Poolbeg Pharma surges as flu trial begins
Some of the biggest movers up and down on Aim over the past week
Poolbeg Pharma says green light for flu drug trial is a 'major milestone'
Researchers will formally commence the trial of POLB 001 on July 22